Bernardo Bonanni
YOU?
Author Swipe
View article: Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis
Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis Open
Cancer cells exhibit metabolic flexibility between anaerobic glycolysis and oxidative phosphorylation. Preclinical data showed that metformin, an oxidative phosphorylation inhibitor, combined with fasting-induced hypoglycemia led to activa…
View article: Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer Open
View article: Impact of Epigenome-Wide Methylation and Breast Cancer Recurrence in Women Tested Negative for BRCA Genes: The Breast Methylation Risk (BREMERI) Study
Impact of Epigenome-Wide Methylation and Breast Cancer Recurrence in Women Tested Negative for BRCA Genes: The Breast Methylation Risk (BREMERI) Study Open
Background and Aim: DNA methylation may contribute to a worsening in breast cancer (BC). Methods: We conducted a matched case–control study to investigate the contribution of DNA methylation (DNAm) in breast cancer recurrence risk. Genome-…
View article: Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus Open
View article: Can Family Motivation Enhance Men’s Uptake of Cascade Screening for Familial <i>BRCA1/2</i> Mutations?
Can Family Motivation Enhance Men’s Uptake of Cascade Screening for Familial <i>BRCA1/2</i> Mutations? Open
Pathogenic variants in the BRCA1 and BRCA2 genes increase the relative and absolute risks of developing breast, ovarian, prostate, and pancreatic cancer. Clinical guidelines recommend cascade screening (CS) to enhance the identification of…
View article: Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention Open
View article: Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in pre-menopausal women.
View article: Data from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Data from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Purpose:Low-dose tamoxifen 5 mg/day (babytam) for 3 years can decrease the incidence of new breast cancer events in women with breast intraepithelial neoplasia by 42% with limited toxicity, which provides a new treatment option for these d…
View article: Supplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Representativeness of Study Participants
View article: Supplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in post-menopausal women.
View article: Supplementary Figure S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
CONSORT diagram.
View article: Supplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Main subject characteristics at baseline (n = 406)
View article: Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Time-course of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio in all women.
View article: Supplementary Table S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Mean event rate (per 1000 person-years) stratified by treatment arm, menopausal status, and baseline E2, SHBG, E2/SHBG ratio at 10 years of follow-up.
View article: Supplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Mean event rate (per 1000 person-years) stratified by treatment arm, menopausal status, and baseline IGF-I, IGFBP-3, IGF-I/IGFBP-3 at 10 years of follow-up.
View article: Supplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Kaplan-Meier estimates of cumulative incidence of breast cancer events stratified by baseline biomarker levels and treatment arms.
View article: 281P Prognostic significance of germline BRCA1 and BRCA2 pathogenetic variants in patients with HR+/HER2- early lobular carcinoma
281P Prognostic significance of germline BRCA1 and BRCA2 pathogenetic variants in patients with HR+/HER2- early lobular carcinoma Open
View article: A Multi‐Level Analysis of Barriers and Promoting Factors to Cascade Screening Uptake Among Male Relatives of <i>BRCA1/2</i> Carriers: A Qualitative Study
A Multi‐Level Analysis of Barriers and Promoting Factors to Cascade Screening Uptake Among Male Relatives of <i>BRCA1/2</i> Carriers: A Qualitative Study Open
Background Pathogenic variants in the BRCA1/2 genes significantly elevate risks of breast, ovarian, prostate, and pancreatic cancer. Clinical guidelines recommend cascade screening (CS) to identify at‐risk family members and advance geneti…
View article: Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Purpose: Low-dose tamoxifen 5 mg/day (babytam) for 3 years can decrease the incidence of new breast cancer events in women with breast intraepithelial neoplasia by 42% with limited toxicity, which provides a new treatment option for these …
View article: Germline Testing in Breast Cancer: A Single-Center Analysis Comparing Strengths and Challenges of Different Approaches
Germline Testing in Breast Cancer: A Single-Center Analysis Comparing Strengths and Challenges of Different Approaches Open
Background/Objectives: Compared to single gene testing (SGT), multigene panel testing (MGPT) improves pathogenic variants (PVs) detection. However, MGPT yields complex results, including secondary findings, heterozygous PVs in recessive ge…
View article: Metachronous colorectal cancer risks after extended or segmental resection in <i>MLH1</i>, <i>MSH2</i>, and <i>MSH6</i> Lynch syndrome: multicentre study from the Prospective Lynch Syndrome Database
Metachronous colorectal cancer risks after extended or segmental resection in <i>MLH1</i>, <i>MSH2</i>, and <i>MSH6</i> Lynch syndrome: multicentre study from the Prospective Lynch Syndrome Database Open
This first prospective observational study evaluates the impact of extended versus segmental colorectal surgery on the risk of metachronous colorectal cancer (CRC) in patients with Lynch syndrome, analyzing data from the Prospective Lynch …
View article: <i>MLH1</i> promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of <i>MLH1</i> gene?
<i>MLH1</i> promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of <i>MLH1</i> gene? Open
Lynch syndrome is a genetic condition predisposing to cancer, particularly colorectal cancer and endometrial cancer, due to germline mutations in MisMatch Repair genes. More rarely, Lynch syndrome is the result of a constitutional MLH1 pro…
View article: Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies
Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies Open
Women carrying pathogenic/likely pathogenic (P/LP) variants in moderate- or high-penetrance genes have an increased risk of developing breast cancer. However, most P/LP variants associated with breast cancer risk show incomplete penetrance…
View article: Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies
Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies Open
Women carrying pathogenic/likely pathogenic (P/LP) variants in moderate- or high-penetrance genes have an increased risk of developing breast cancer. However, most P/LP variants associated with breast cancer risk show incomplete penetrance…
View article: Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer
Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer Open
Background Breast Cancer (BC) prevention strategies range from lifestyle changes such as increasing physical activity and reducing body weight to preventive drugs like tamoxifen, known to reduce BC incidence in high-risk women. Sex Hormone…
View article: Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules Open
The drug’s activity at the target tissue could help to define the minimal effective dose to promote cancer preventive therapy. Here we present exemestane and sex hormone concentrations within breast tissue from a presurgical study of alter…
View article: A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial
A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial Open
Obesity is a risk factor for postmenopausal breast cancer (BC), and evidence suggests a role for adiponectin in the relationship between obesity and BC. We investigated whether adiponectin or other biomarkers mediate the effect of body mas…
View article: <i>CDH1</i> Genotype Exploration in Women With Hereditary Lobular Breast Cancer Phenotype
<i>CDH1</i> Genotype Exploration in Women With Hereditary Lobular Breast Cancer Phenotype Open
Importance Pathogenic or likely pathogenic (P/LP) germline CDH1 variants are associated with risk for diffuse gastric cancer and lobular breast cancer (LBC) in the so-called hereditary diffuse gastric cancer (HDGC) syndrome. However, in so…
View article: Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ Open
View article: Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study
Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study Open
Background and aim: The involvement of cholesterol in cancer development remains a topic of debate, and its association with breast cancer has yet to be consistently demonstrated. Considering that circulating cholesterol levels depend on s…